Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VALIANTLAB.NS
Strong BuyHot AirValiant Laboratories Limited · Healthcare · India · $65M · Avg Vol: $204K/d
83
StockRankGet insider-trade alerts
Q
47
V
37
M
95
P/E (TTM)
42.5x
ROE
-1.1%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3.3B | 1.8B | 1.3B | 2.4B | -10.7% | 3.1B |
| EPS (INR) | 6.19 | 0.12 | -0.47 | -0.65 | -98.1% | 2.82 |
| Shares | 46.8M | 46.8M | 46.8M | 54.3M | +16.0% | 54.3M |
| Debt | 602.2M | 767.1M | 1.2B | 462.1M | -8.4% | 462.1M |
| Equity | 1.0B | 2.4B | 2.3B | 3.1B | 45.7% | — |
| Op CF | 560.5M | 18.9M | 13.1M | -104.3M | -84.7% | -104.3M |
| Inv CF | -551.7M | -1.4B | -527.7M | 72.5M | — | — |
| Fin CF | -9.3M | 1.5B | 446.5M | 17.9M | — | — |
Loading 1Y...
PRICE (1Y)+94.1%
SMA 50SMA 200
Close
$1.26
RSI (14)
72.8
52W High
$1.26
From 52W High
1.0%
SCORE BREAKDOWN
Quality
47
ROIC
8.0%64.7
ROE
-1.1%43.2
GP/Assets
17.4%39.1
Op. Margin
22.9%86.3
FCF/Assets
-9.6%30.0
Piotroski
316.1
Int. Cover
9.5x61.0
D/E Ratio
0.15x55.8
Current Ratio
1.91x37.0
Value
37
P/E (TTM)
42.5x26.1
EV/EBITDA
19.8x34.8
P/FCF
—N/A
P/B
2.1x60.4
P/S
2.1x67.2
Div Yield
—N/A
Momentum
95
52W High %
100%99.9
RS 6M
119%97.7
SMA 50/200
1.11x77.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
1059%98.6
FUNDAMENTALS
Market Cap
$65M
P/E (Forward)
—
Gross Margin
26.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VALIANTLAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VALIANTLAB.NS | Valiant Laboratories Limited(you) | $65M | 83 | Strong Buy |
| AMANTA.NS | Amanta Healthcare Limited | $83M | 81 | Strong Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
| ALBERTDAVD.NS | Albert David Limited | $51M | 93 | Strong Buy |
| ZIMLAB.NS | ZIM Laboratories Limited | $73M | 67 | Buy |
| WANBURY.NS | Wanbury Limited | $91M | 69 | Buy |
| ANUHPHR.NS | Anuh Pharma Limited | $101M | 94 | Strong Buy |
| KILITCH.NS | Kilitch Drugs (India) Limited | $69M | 58 | Hold |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited | $165M | 94 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.7x · Gross margin 59.4%